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B cell activating factor of the tumor necrosis factor (TNF) family (BAFF) and a proliferation-
inducing ligand (APRIL) are closely related ligands within the TNF superfamily that play 
important roles in B lymphocyte biology. Both ligands share two receptors—transmembrane 
activator and calcium signal–modulating cyclophilin ligand interactor (TACI) and B cell 
maturation antigen (BCMA)—that are predominantly expressed on B cells. In addition, BAFF 
specifically binds BAFF receptor, whereas the nature of a postulated APRIL-specific receptor 
remains elusive. We show that the TNF homology domain of APRIL binds BCMA and TACI, 
whereas a basic amino acid sequence (QKQKKQ) close to the NH
 
2
 
 terminus of the mature 
protein is required for binding to the APRIL-specific “receptor.” This interactor was identified 
as negatively charged sulfated glycosaminoglycan side chains of proteoglycans. Although 
T cell lines bound little APRIL, the ectopic expression of glycosaminoglycan-rich syndecans or 
glypicans conferred on these cells a high binding capacity that was completely dependent on 
APRIL’s basic sequence. Moreover, syndecan-1–positive plasma cells and proteoglycan-rich 
nonhematopoietic cells displayed high specific, heparin-sensitive binding to APRIL. Inhibition 
of BAFF and APRIL, but not BAFF alone, prevented the survival and/or the migration of newly 
formed plasma cells to the bone marrow. In addition, costimulation of B cell proliferation by 
APRIL was only effective upon APRIL oligomerization.
 
 
 
Therefore, we propose a model whereby 
APRIL binding to the extracellular matrix or to proteoglycan-positive cells induces APRIL 
oligomerization, which is the prerequisite for the triggering of TACI- and/or BCMA-mediated 
activation, migration, or survival signals.
 
A proliferation-inducing ligand (APRIL) and
B cell activating factor of the TNF family
(BAFF, also known as BLyS and TALL-1) are
closely related ligands of the TNF family that
share two receptors: B cell maturation antigen
(BCMA) and transmembrane activator and
calcium signal–modulating cyclophilin ligand
interactor (TACI). BAFF binds additionally to
BAFF receptor (BAFF-R, also known as BR3;
reference 1). APRIL binds BCMA with a
higher affinity than BAFF, suggesting that they
form a biologically relevant ligand–receptor
pair (2, 3). Studies with transgenic and knock-
out mice have revealed an essential role for
BAFF and BAFF-R in the maturation and sur-
vival of peripheral B cells (1), whereas TACI
functions mainly as a negative regulator of
BAFF and/or APRIL signals (4), and BCMA
may be relevant to long-lived plasma cell sur-
vival (5). APRIL (and BAFF) can induce a
CD40L–independent isotype switch to IgA in
vitro (6), which corresponds with the observa-
tion that one line of APRIL knockout mice
displays reduced IgA responses to mucosal im-
munization (7). The immunological phenotype
of APRIL-deficient mice is milder than that of
BAFF or BAFF-R–deficient mice, because the
BAFF and BAFF-R axis, which is essential for
B cell survival, is not affected in these mice,
and BAFF can probably replace some of APRIL’s
functions.
In contrast to BAFF, APRIL is also expressed
in several tumor tissues or cell lines, such as colon
carcinomas. The role of APRIL in these tissues is
unknown, but APRIL has been reported to pro-
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mote proliferation of certain cell lines, including fibroblasts and
malignant glioblastoma (8, 9). Administration of BCMA:Fc re-
tards tumor growth in nude mice injected with human colon
carcinoma HT29 cells and, to a lesser extent, human lung carci-
noma A549 cells (3). Recombinant APRIL binds to several cell
lines that do not express detectable mRNA for TACI and
BCMA, suggesting that an additional APRIL-specific receptor
exists. The binding to this receptor is reduced by predepletion
of APRIL with BCMA:Fc, but it is not competitively inhibited
when APRIL and BCMA:Fc are added to cells simultaneously.
This suggests that the APRIL-specific receptor expressed on
nonhematopoietic cells binds APRIL with a much higher affin-
ity than BCMA, or at a distinct binding site (3). Both APRIL
and BAFF are released in a soluble form by proteolytic process-
ing at a furin consensus sequence (R X R/K R; reference 1).
This leaves a short NH
 
2
 
-terminal extension in front of the TNF
homology domain in the cleaved, mature forms of APRIL and
BAFF. In the case of APRIL, this sequence is basic in nature
(Fig. 1 A). We show that the basic, mature NH
 
2
 
-terminal se-
quence of APRIL allows binding to sulfated glycosaminogly-
cans, which most likely represents the proposed, but as yet un-
characterized, APRIL-specific binding partner.
 
RESULTS
The mature NH
 
2
 
-terminal sequence of APRIL is required for 
binding to the APRIL-specific binding partner
 
We have previously shown that APRIL displayed significant
binding to various cell lines that did not express the two
known APRIL receptors, TACI and BCMA. Consistent
with the absence of BCMA and TACI, these cells did not in-
teract with BAFF, suggesting the existence of an additional,
widely distributed receptor for APRIL with little or no affin-
ity for BAFF (3). The mature form of APRIL (designated
here as APRIL A88) starts at Ala 88 and contains 10 amino
acids in front of the TNF homology domain (Fig. 1 A). The
removal of this sequence was initially performed to assess the
impact on the production yield of APRIL, which was indeed
increased about threefold
 
 
 
(unpublished data). APRIL H98
retained its ability to bind both BCMA and TACI, but this
deletion completely abolished binding to the putative endog-
enous APRIL-specific binding partner on the same cells (Fig.
1 B, ligand only). Importantly, these results were also ob-
tained with the murine proteins (unpublished data).
The staining pattern of BAFF and APRIL was examined
in the presence of soluble BCMA, which acted as a decoy
receptor and prevented the binding of APRIL H98 and
APRIL A88 to cell-associated TACI and BCMA. Soluble
BCMA also abolished the binding of BAFF to cell-associated
BCMA and reduced the binding to BAFF-R and TACI.
This was consistent with the fact that BAFF has a lower af-
finity for BCMA than for BAFF-R and TACI. However,
soluble BCMA did not affect the binding of APRIL A88 to
the endogenous APRIL-specific interactor (Fig. 1 B, ligand 
 
 
 
soluble BCMA). A control decoy receptor, soluble CD40,
had no effect (unpublished data). These studies indicate that
the binding of APRIL A88 to the APRIL-specific binding
partner requires a sequence within the 10 NH
 
2
 
-terminal amino
acids of mature APRIL, which is distinct from the binding
site to BCMA and TACI.
 
Heparin competes with the APRIL-specific interactor for 
the binding of APRIL
 
The mature NH
 
2
 
-terminal sequence of APRIL contains a
cluster of basic amino acid residues that are absent in BAFF
Figure 1. The NH2 terminus of mature APRIL is required for inter-
action with HEK-293T cells, but not with BCMA and TACI. (A) The 
sequence of APRIL and BAFF is depicted around the mature NH2 terminus. 
The box outlines the furin recognition sequence. The open arrow points to 
the cleavage site. The bold letters depict basic amino acids. The line on top 
of the alignment indicates the start of the TNF homology domain. The 
asterisk represents the 32–amino acid sequence insertion in murine BAFF. 
(B) 293T cells cotransfected with the indicated receptors, plus an EGFP 
tracer, were stained with Fc:BAFF, Fc:APRIL H98, or Fc:APRIL A88. Pentameric 
BCMA:COMP-Flag (soluble BCMA) and heparin were used as competitors, 
either alone or in combination. Both axes show fluorescent intensity on 
a logarithmic scale (100–104). The small residual binding of BAFF to BCMA 
in the presence of soluble BCMA, but not in the presence of BCMA plus 
heparin, does not reflect a specific effect of heparin on BAFF binding, but 
rather an experimental variation. This was not observed in three other 
independent experiments. 
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(Fig. 1 A). To test whether this cationic stretch of amino ac-
ids could interact with negatively charged structures, such as
phospholipids or anionic sugars, on the cell surface, the
highly negatively charged heparin polymer was added during
the staining procedure. Heparin did not affect the binding of
BAFF and APRIL to BCMA and TACI, but specifically
abolished the binding of APRIL A88 to the endogenous
APRIL-specific interactor (Fig. 1 B, ligand 
 
 
 
 heparin). As
expected from this result, the combination of soluble BCMA
and heparin strongly reduced the binding of APRIL A88 to
the endogenous APRIL-specific interactor, as well as BCMA
and TACI (Fig. 1 B).
The competition with heparin suggested that APRIL A88
might bind heparin directly. Interaction studies confirmed
that Flag-tagged APRIL and BAFF constructs bearing various
deletions at the mature NH
 
2
 
 terminus all bound BCMA:Fc,
but the binding to heparin-Sepharose required the basic se-
quence that was mapped down to six amino acids (sequence
92–97, QKQKKQ). Importantly, APRIL processed by en-
dogenous furin also interacted with heparin, ruling out the
possibility that the binding was contributed by the Fc or Flag
tags in other recombinant constructs (Fig. 2). A chimeric
ligand with the mature NH
 
2
 
-terminal sequence of APRIL
fused to BAFF failed to bind heparin and the endogenous
APRIL-specific interactor (Fig. 2 and not depicted). In addi-
tion, a synthetic peptide comprising amino acids 88–99 of
APRIL did not competitively inhibit the binding of APRIL
A88 to the endogenous APRIL-specific interactor (unpub-
lished data). This suggests that the basic NH
 
2
 
-terminal se-
quence of APRIL is necessary, but not solely sufficient, for
binding to heparin and to the endogenous APRIL-specific
binding partner. Based on the crystal structure of the APRIL–
BCMA complex (10), three basic amino acid residues of
APRIL were substituted by those found at the corresponding
positions of BAFF (R129S, R172S, and H203E). These resi-
dues contribute to a basic surface on APRIL that is distinct
from the binding site for BCMA and TACI (Fig. 2 C). Their
mutation specifically affected binding to heparin, but not to
BCMA (Fig. 2 A), strongly suggesting that both the basic sur-
face and the basic NH
 
2
 
-terminal sequence of APRIL are re-
quired for heparin binding. Interestingly, the mature NH
 
2
 
-
terminal sequences of BAFF and APRIL significantly affected
SDS-PAGE migration, with the BAFF sequence resulting in a
higher apparent molecular mass than the APRIL sequence
(Fig. 2). This may reflect differences in SDS binding or indi-
cate a rigid conformation of the BAFF sequence. Curiously,
the BAFF sequence GPEET is found as a repetitive sequence
in procyclin, which is a surface antigen of a trypanosomatid
protozoan parasite known to migrate with an abnormally high
apparent molecular mass by SDS-PAGE (11).
 
Sulfated glycosaminoglycan side chains of proteoglycans are 
the APRIL-specific binding partner
 
Heparin consists of alternating residues of glucuronic acid (or
its 5-epimer iduronic acid) and 
 
N
 
-acetyl-galactosamine in
which both sugar residues can be mono- or disulfated,
thereby providing additional negative charges. Because of its
soluble nature, heparin alone is not likely to be the endoge-
nous APRIL-specific binding partner, but heparin-like gly-
cosaminoglycans are present in membrane-bound proteogly-
cans. Treatment of 293T cells with a sulfation inhibitor,
chlorate, resulted in markedly decreased binding of both
mouse and human APRIL A88, but did not affect the bind-
ing of APRIL to transfected BCMA (Fig. 3 A and not de-
picted). To demonstrate more directly the interaction of
APRIL A88 with proteoglycans, Jurkat cells were selected
because they express relatively low levels of the endogenous
APRIL-specific interactor. Transfected Jurkat cells expressing
various proteoglycans (syndecan-1, -2, or -4, or the gly-
Figure 2. The NH2 terminus of mature APRIL and other basic residues 
are required for heparin binding. (A) Flag-tagged ligands were immuno-
precipitated with either BCMA:Fc or heparin-Sepharose. Naturally processed, 
untagged APRIL was also used. Proteins were detected by immunoblot with 
anti-Flag or anti-APRIL mAbs as indicated. (B) Schematic representation of 
the constructs used in A. (C) Structure of the APRIL–BCMA complex (refer-
ence 10), showing one subunit of the trimer. Side chains of all basic amino 
acid residues that are present on the upper surface of APRIL are shown 
(gray, common to APRIL and BAFF; black, APRIL specific [R129, R172, and 
H203]). The basic NH2 terminus of mature APRIL, which is only partially 
apparent in the crystal structure, comprises K97. A heparin fragment is 
shown above its proposed binding site. APRIL, BCMA, and heparin were 
drawn using the PDB atomic coordinate files 1XU2 and 1FQ9. 
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colipid-anchored glypican-1) gained robust and specific bind-
ing to APRIL A88 (Fig. 3 B). This indicates that the binding
is dependent on the glycosaminoglycan side chains rather
than on specific interactions with the polypeptide portion of
either syndecans or glypicans. Collectively, our results strongly
suggest that the endogenous APRIL-specific binding partners
expressed by 293T and other cell lines are sulfated glycosami-
noglycan side chains of cell surface proteoglycans.
 
Expression of APRIL and BAFF receptors in cell lines 
and mouse lymphocytic cells
 
We determined the binding patterns of BAFF and APRIL
on various cell lines, taking advantage of the possibility to ef-
ficiently inhibit APRIL binding to glycosaminoglycans with
heparin. The high binding of APRIL to nonhematopoietic
cell lines, such as HT-29 and SW480 colorectal adenocarci-
nomas, A549 lung carcinoma, 293 embryonic kidney cells,
and NIH-3T3 murine fibrobasts, was completely inhibited
by heparin. BAFF did not bind these cell lines, indicating a
proteoglycan-dependent binding (Fig. 1 and not depicted).
In Burkitt lymphoma BJAB cells, the moderate binding of
APRIL was proteoglycan dependent, whereas BAFF gave a
strong specific binding, consistent with the high expression
of BAFF-R in these cells (12). The APRIL staining of the
TACI-positive IM-9 B lymphobast cells (13) was caused by
both heparin-sensitive and heparin-insensitive (TACI) sites.
U266 plasmacytoma/myeloma cells stained strongly in the
absence of heparin; however, despite expressing high amounts
of BCMA message, they bound only small, but significant,
amounts of APRIL in the presence of heparin (unpublished
data). The latter result is consistent with the original paper
indicating poor expression of surface BCMA in these cells
(14).
We investigated the binding of BAFF and APRIL to pri-
mary lymphocytes from lymph nodes in which large num-
bers of plasma cells had been elicited by infection with a
mouse mammary tumor virus (15). BAFF bound lymph
node B cells and plasma cells, but not T cells. APRIL bound
B, T, and plasma cells. In the presence of heparin, binding to
T and B cells was abolished, but specific APRIL binding on
plasma cells was maintained. This suggests that B cells express
mainly BAFF-R, whereas plasma cells express BAFF-R,
TACI, and/or BCMA (including at least one of the latter
two receptors), in addition to proteoglycans (Fig. 4). To-
gether, these results indicate that APRIL binding to nonhe-
matopoietic cells is glycosaminoglycan mediated. The same
holds true for hematopoietic cells, except that binding to
TACI and/or BCMA in plasma cells and TACI-positive cell
lines also contributes to the binding.
 
APRIL oligomerization is required for B cell costimulation
 
Although BAFF and APRIL costimulate the proliferation of
splenic B cells (16), we initially observed this effect with
BAFF but not APRIL. We therefore wondered whether
APRIL, like CD40L, might require a higher order oligomer-
Figure 3. APRIL binds the sulfated glycosaminoglycan side chains 
of proteoglycans. (A) 293T cells grown in the presence or absence of the 
sulfation inhibitor chlorate were stained with Fc versions of the indicated 
human (h) or murine (m) APRILs. (B) Jurkat cells cotransfected with various 
human syndecan or glypican expression constructs and an EGFP tracer 
were stained with Fc versions of human BAFF, APRIL H98, or APRIL A88. 
Both axes show fluorescent intensity on a logarithmic scale (100–104).
Figure 4. APRIL binding to primary syndecan-1–positive plasma cells. 
(A) Flow cytometry analysis of draining popliteal lymph nodes from mouse 
mammary tumor virus–infected mouse. B220 and CD138 stainings were used 
to define B cell (B), plasma cell (PC), and T cell and other cell (T) populations as 
indicated. (B) Staining of cell populations defined in A with Fc versions of 
mouse BAFF or APRIL A88, in the presence or absence of heparin. 
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ization in order to successfully deliver a coproliferative signal
(17). Indeed, antibody-mediated cross-linking of APRIL and
CD40L induced a significant costimulation of B lymphocyte
proliferation, whereas BAFF, though potentiated by cross-
linking, was already active on its own. A control ligand, ec-
todysplasin A (EDA), did not costimulate B cells under any
conditions (Fig. 5 A). We also tested for the involvement of
the glycosaminoglycan binding site of APRIL by adding
heparin in the assay, based on the hypothesis that heparin
could cross-link APRIL and render it signaling competent.
However, only minor costimulation of B cell proliferation
was obtained with APRIL A88 plus heparin, suggesting that
heparin is not an optimal cross-linker under our experimen-
tal conditions (Fig. 5 A). Glycosaminoglycan-dependent oli-
gomerization was not observed at all with APRIL H98 and
CD40L (Fig. 5). Heparin did not further enhance the activity
of APRIL cross-linked with antibodies (unpublished data).
The costimulatory effect of cross-linked APRIL H98 cannot
be mediated by BAFF-R or proteoglycans, which are not
recognized by this ligand. Transitional type 2 B cells and
marginal zone B cells, which are specific to the spleen, ex-
press TACI constitutively and may therefore represent a tar-
get for APRIL (18, 19). However, the observation that
APRIL costimulated blood and lymph node B cells, in addi-
tion to splenic B cells (Fig. 5 B), suggests that inducible
TACI (18) may mediate APRIL costimulatory effects.
 
Impaired generation of bone marrow plasma cells upon 
blockade of APRIL and BAFF but not BAFF alone
 
We investigated the possible implications of APRIL in the
biology of newly formed plasma cells. For this purpose, an
antibody response was first elicited with nitrophenyl-conju-
gated chicken gammaglobulin (NP-CGG) in alum. This
model antigen induces a germinal center reaction after 5–7 d
(20), which is followed by the migration of plasma cells to
the bone marrow where they can be detected as early as day
11 after immunization. Mice were treated 6 d after immuni-
zation with either BCMA:Fc (which blocks both BAFF and
APRIL) or BAFF-R:Fc (which blocks only BAFF) and ana-
lyzed 5 d later. This regimen blocked the treatment’s impact
on antigen-specific precursor cells and specifically assessed
the role of BAFF and APRIL depletion in the fate of newly
formed plasma cells. Although the treatment reduced the to-
tal number of splenic IgG1-switched plasma cells and the
IgG1 antibody titer in serum about twofold, we noticed no
differences between BAFF-R:Fc and BCMA:Fc treatments,
suggesting that this effect was BAFF mediated (Fig. 6, A and
C). However, the frequency of specific IgG1-secreting
Figure 5. Antibody-mediated cross-linking of APRIL potentiates 
B cell costimulation. (A) Purified splenic mouse B cells were stimulated 
with anti-IgM antibodies and costimulated for 3 d with the indicated Flag-
tagged murine ligands, in the presence or absence of anti-Flag antibody or 
heparin. Proliferation was monitored by thymidine incorporation. (B) B cells 
purified from spleen, lymph nodes, and blood where stimulated as in A with 
the indicated Flag-tagged ligands in the presence of anti-Flag antibody.
Figure 6. BAFF and APRIL are important for the migration or sur-
vival of newly formed plasma cells to the bone marrow. 6 d after 
immunization with NP21–CGG, mice were treated with normal IgG, BCMA:
Fc, or BAFFR:Fc. 5 d after treatment, ELISPOT assays were used to deter-
mine the frequencies of specific plasma cells (A) in the spleen and (B) in 
the bone marrow. (C) Titers of specific IgG1 in sera were determined by 
ELISA and normalized against the value obtained for a 1:50,000 dilution of 
hyperimmunized mouse serum. Results from two representative experiments 
with a total number of 8–10 mice in each treatment group are shown. The 
experiment using four to five mice per group was repeated four times 
with similar results. P-values are indicated above the groups when signifi-
cantly different (P   0.05) from the control-treated animals. 
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plasma cells in the bone marrow was dramatically decreased
in mice treated with BCMA:Fc, but not BAFF-R:Fc. This
suggests that APRIL, either alone or together with BAFF
(but not BAFF alone), is required for the migration and/or
maintenance of bone marrow resident cells early in the pri-
mary immune response (Fig. 6 B).
 
DISCUSSION
 
After the identification of APRIL and BAFF some years ago,
several laboratories have attempted to identify their cognate
receptors. Interestingly, published results using unbiased ex-
pression cloning approaches have invariably been performed
with BAFF and not APRIL (12, 16, 21–26). Expression clon-
ing is strongly facilitated by a low background of the screen-
ing ligand, a condition that is not fulfilled by APRIL which
binds to most cells via glycosaminoglycan interactions. Al-
though the binding of proteins to heparin or to heparansulfate
is a frequent event, it has not been previously described in the
TNF family. Is it therefore legitimate to wonder whether
APRIL is unique in this respect, or whether glycosaminogly-
can binding is an important intrinsic feature within the TNF
family. In contrast to APRIL, BAFF does not interact with
glycosaminoglycans, but at least one other TNF family mem-
ber, EDA, does (unpublished data). It remains to be deter-
mined whether other ligands share this property.
We have mapped the heparin-binding region within the
NH
 
2
 
-terminal sequence of mature APRIL. However, this
region alone is insufficient to mediate glycosaminoglycan
binding, which suggests that additional cationic features of
APRIL are involved. Indeed, the surface of APRIL that har-
bors the basic mature NH
 
2
 
 terminus also exposes several ad-
ditional basic amino acids (Arg129, Arg172, and His203; ref-
erence 10) that are required for efficient binding to heparin,
and that are absent at the corresponding positions of BAFF.
These data strongly suggest the existence of an extended gly-
cosaminoglycan binding site in APRIL (Fig. 2 C). It is fre-
quently observed that heparin-binding sites do not only rely
on linear amino acid sequences but also on patches of amino
acid residues scattered over the protein surface, as is the case
with many chemokines (27). Although APRIL contains an-
other basic surface at the site contacted by BCMA (28), it is
unlikely to participate in glycosaminoglycan recognition be-
cause it lies on the opposite face of APRIL and competition
with BCMA was not observed.
TNF family ligands adopt a homotrimeric structure that is
competent for receptor binding. However, binding to recep-
tors may not be sufficient to induce productive signaling
within the cell. Indeed, a higher order oligomerization of
several trimeric TNF family ligands, such as FasL and
CD40L, is required for the efficient induction of a biological
response (17, 29). It is believed that the cross-linking of solu-
ble trimeric ligands mimics the membrane-bound form of the
ligand. Our results indicate that APRIL belongs to the cate-
gory of TNF ligands that requires cross-linking to exert activ-
ity, at least with respect to B cell costimulation. This is, how-
ever, difficult to reconcile with the observation that APRIL is
entirely released in a putatively inactive soluble form after in-
tracellular processing (30). It is therefore tempting to propose
that soluble APRIL, cross-linked to cell-associated or matrix
proteoglycans by virtue of its heparansulfate-binding site,
may regain an activity similar to that of the membrane-bound
form. Heparansulfates can provide or reinforce physical links
between proteins. For instance, heparin as an anticlotting
agent not only induces conformational changes in anti–
thrombin III, resulting in the exposure of the reactive site
loop that acts as a bait for active thrombin, but also bridges
thrombin with its inhibitor (31, 32). Similarly, the signaling
of fibroblast growth factor (FGF) through its receptor
(FGFR) tyrosine kinase is dependent on cell surface heparan-
sulfate that connects individual FGF–FGFR complexes to
yield an active signaling platform (33, 34). In a similar man-
ner, APRIL cross-linked by proteoglycans could be impor-
tant in mediating the survival of syndecan- and BCMA-posi-
tive plasma cells. Although our attempts to activate APRIL
with heparin had limited success, it is known that the fine
structures of heparin and the glycosaminoglycan side chains
of proteoglycans are quite different and heparin is therefore
not necessarily expected to mimic cell surface proteoglycans
(35). Alternative hypotheses regarding the active form of
APRIL exist. For example, a fraction of endogenous APRIL
may remain membrane bound in the form of a chimeric pro-
tein formed as a result of alternative splicing between the
closely located genes for TWEAK and APRIL (36).
Not only do heparansulfates modulate the activity of
binding partners by cross-linking or inducing conformational
changes, but they are also used for the generation of chemo-
tactic gradients. The basis of chemotaxis for most chemokines
relies on their concentration-dependent binding to cell sur-
faces or matrix heparansulfates (27, 37). Therefore, it is an in-
triguing possibility that heparansulfate-bound APRIL not
only regulates plasma cell survival but also trafficking. Our
observation that APRIL, either alone or in conjunction with
BAFF, is important for the bone marrow tropism of newly
generated plasma cells (and/or for their survival in this loca-
tion) would agree with this hypothesis. Alternative interpre-
tations are, however, possible: for instance, APRIL may in-
duce upregulation of chemokine receptors that, in turn,
would favor migration to the bone marrow.
Multiple myeloma and various leukemias rely, at least in
part, on autocrine antiapoptotic signals delivered by APRIL
and BAFF (38–41). Moreover, mice that are transgenic for
APRIL develop lymphoid tumors that are derived from the
peritoneal B-1 B cell population (42). Because APRIL alone
displays little or no biological activity, only cell-bound
APRIL may exert its oncogenic effects via TACI and/or
BCMA, both of which are activators of the antiapoptotic
NF–
 
 
 
B pathway (1). Proteoglycans are well-known tumor
markers that can be either up- or down-regulated (35, 43,
44). For example, the tumor-specific splice variants of CD44
carry, among other features, a heparansulfate side chain at- 
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tached to the variant exon 3 that is absent in the standard
form of CD44 (45). Both syndecan-1 and CD44 variants are
expressed in myeloma and, in addition to binding growth
factors, promote adhesion to bone marrow stromal cells that
become stimulated for IL-6 secretion (43, 46, 47). IL-6 acts
as a survival factor for myeloma cells, and its action is syner-
gized by BAFF and APRIL (38, 41). Hematopoietic cells ex-
pressing proteoglycans could thus accumulate APRIL, ren-
dering it active for TACI and/or BCMA signaling and
triggering autocrine growth and tumorigenesis. APRIL has
also been shown to stimulate the proliferation of tumor cells
that lack TACI and BCMA. However, compared with the B
cell costimulatory activity, this effect is marginal. It may still
be that APRIL induces survival directly through syndecans
that can deliver signals through their intracellular tails upon
binding to ligands (48), which may explain the observation
that APRIL H98 failed to stimulated tumor cell growth (un-
published data). In any case, the inhibition of APRIL by
BCMA:Fc or specific other inhibitors that interfere with
APRIL should be considered in cancer therapy.
 
MATERIALS AND METHODS
 
Cell lines and reagents.
 
HEK-293T, NIH-3T3, SW480, A549, and
HT29 cells were grown in DMEM with 10% FCS plus antibiotics. Where
indicated, 50 mM sodium chlorate was added in culture medium for 4 d be-
fore the analysis. Jurkat, U266, BJAB, and IM9 cells were grown in RPMI
1640 with 10% FCS plus antibiotics. Heparin (Liquemin, 5,000 IU/ml) was
purchased from Roche Pharma, and heparin-Sepharose was purchased from
GE Healthcare.
 
Expression constructs.
 
Expression vectors for Flag ligands and Fc:ligands
have been described previously (17). Ligands were cloned either with a Flag
or an Fc tag (amino acid numbers are given in parentheses): hBAFF-A134
(134–285); hBAFF-G137 (137–285); hBAFF-V142 (142–285); hAPRIL-
A88 (88–233); hAPRIL-A88 (88–233 with mutations R129S/R172S/
H203E); hAPRIL-Q92 (92–233); hAPRIL-H98 (98–233); mAPRIL-A88
(88–232); mAPRIL-H98 (98–232); mBAFF (127–309); mCD40L (115–
260); mEDA1 (245–391); and the fusion proteins hAPRIL (88–96)–
hBAFF (142–285) and hBAFF (134–142)–hAPRIL (98–233). The expres-
sion vector for full-length APRIL has been described previously (8).
The extracellular domains of hBCMA (2–54), hTACI (2–159), and
hBAFF-R (2–71) were fused NH
 
2
 
-terminally to a signal peptide and
COOH-terminally to a portion of hTRAILR3 (157–259) that included the
GPI addition signal. hBCMA (2–54) and hCD40 (1–193) were also ex-
pressed as fusion proteins with the pentamerization domain of human carti-
lage oligomeric matrix protein (hCOMP, aa 33–80) and a Flag tag (49).
BCMA:Fc has been described previously (3). BCMA:Fc and BAFF-R:Fc
used for in vivo experiments were produced as described previously (50).
Expression plasmids for full-length hSyndecan-1-VSV (amino acids [aa]
1–310), hSyndecan-2-VSV (aa 1–206), hSyndecan-4 (aa 1–198), and the
signal peptide-VSV-hGlypican-1 (aa 24–558) were prepared using cDNA
contained in the IMAGE clones 4400058, 2107451, 5201920, and
2536088, respectively (Invitrogen).
 
Transfection.
 
For secreted proteins, transiently transfected HEK-293T
cells were grown in a serum-free Opti-MEM 1 medium for 4–7 d. Superna-
tants were collected and frozen until use. The BCMA:COMP-Flag and
CD40:COMP-Flag containing supernatants were concentrated 20-fold be-
fore use. Protein concentrations were estimated by immunoblot using anti-
Flag or anti-Fc antibodies with purified proteins of known concentration as
standards. Jurkat cells were electroporated with proteoglycan expression con-
structs together with an EGFP tracer plasmid using the transfection solution
V and the electroporation program O-17 (Amaxa Biosystems). After elec-
troporation, Jurkat cells were cultured for 16 h before flow cytometry.
 
Flow cytometry staining.
 
Transfected 293T or Jurkat cells were stained
in 25 
 
 
 
l PBS with 5% FCS containing 5–15 
 
 
 
l of Fc-tagged ligands in
Opti-MEM (10–50 ng per staining), followed by PE-coupled goat anti–
human IgG (Southern Biotechnology Associates, Inc.).
Mice were handled according to institutional and Swiss Federal Veteri-
nary Office guidelines, as well as under the authorization of the Service
Vétérinaire du Canton de Vaud. Plasma cells were generated as described
previously (15). In brief, BALB/c mice were infected in the rear leg with 10
 
 
 
l of 10-fold diluted milk from mouse mammary tumor virus–infected
mice. After 6 d, popliteal lymph nodes were collected that typically con-
tained 10% plasma cells. Cells were treated successively with the following:
(a) anti-CD16/CD32 (as hybridoma supernatants of clone 2.4G2) to block
FcR binding; (b) Fc:mAPRIL A88 or Fc:mBAFF; (c) biotinylated anti-
CD138/syndecan1 (clone 281-2; BD Biosciences); and (d) a mixture of
anti–CD3
 
 
 
-FITC (17A2; BD Biosciences), anti–B220-Cy5 (RA3.6B2; BD
Biosciences), anti–human Ig-PE, and streptavidin-PE–Cy5.5 (eBioscience).
Cells were analyzed using a four-color FACSCalibur flow cytometer and
CellQuest software.
 
Immunoprecipitations.
 
The various Flag-tagged APRIL and BAFF pro-
teins (1 ml of cell supernatant, 
 
 
 
1 
 
 
 
g) were immunoprecipitated with ei-
ther 1 
 
 
 
g BCMA:Fc, followed by protein A–Sepharose beads, or with 10
 
 
 
l of heparin-Sepharose beads (for 16 h at 4
 
 
 
C). Beads were washed with
PBS and eluted by boiling in an SDS-PAGE sample buffer. 1/20 of the elu-
ate was analyzed by Western blotting with anti-Flag M2 mAb (Sigma-
Aldrich) or anti-hAPRIL mAb (Aprily-2; Apotech).
 
Proliferation assays.
 
B cells were isolated from spleens, inguinal lymph
nodes, or the blood of C57BL/6 mice by anti-B220 magnetic bead separa-
tion (Miltenyi Biotec). B cells (10
 
5
 
 cells/well in 200 
 
 
 
l RPMI 1640 with
10% FCS and 5 mM 2-mercaptoethanol) were grown for 48 h with 5 
 
 
 
g/
ml of goat F(ab
 
 
 
)2 anti–mouse 
 
 
 
 chain antibody (Jackson ImmunoResearch
Laboratories) and in the presence of serial dilutions of various Flag-tagged
ligands. The assay was performed in the presence or absence of anti-Flag an-
tibody (1 
 
 
 
g/ml) or heparin (0.01 
 
 
 
l/well, corresponding to 
 
 
 
2.5 
 
 
 
g/ml).
Cells were pulsed for an additional 18 h with 1 
 
 
 
Ci/well of [
 
3
 
H]thymidine,
harvested, and counted by liquid scintillation.
 
Immunizations and treatment with decoy receptors.
 
C57BL/6J
mice used in this study were housed at the Biogen Idec animal facility under
sterile, pathogen-free conditions according to the approved Institutional
Animal Care and Use Committees’ protocol. 6–8-wk-old mice were im-
munized i.p. with 100 
 
 
 
g (4-hydroxy-3-nitrophenyl)acetyl (NP) conju-
gated to chicken 
 
 
 
-globulin (CGG) at 21:1 molar ratio (NP
 
21
 
–CGG conju-
gate; Biosearch Technologies) precipitated in alum (Pierce Chemical Co.).
BCMA-Fc and BAFFR-Fc were described previously (50), and normal hu-
man IgG was used as a control (Jackson ImmunoResearch Laboratories).
250 
 
 
 
g of either reagent was administered by i.p. injection 6 d after immu-
nization. On day 11 after the immunization, the mice were killed to collect
spleen, bone marrow, and sera.
 
Measure of the antibody response.
 
The frequency of antigen-specific
antibody-secreting cells was estimated by ELISPOT using mixed cellulose
esters (HA) 96-well plates (Millipore) coated overnight at 4
 
 
 
C with 50 
 
 
 
g/
ml NP
 
2
 
-BSA or NP
 
17
 
-BSA in PBS. Plates were washed twice with PBS and
blocked for 2 h with culture medium before culture of 3 
 
 
 
 10
 
5
 
 cells/well of
splenocytes or bone marrow cells, for 20 h in DMEM with 5% FCS, and
0.1 mM 2-mercaptoethanol. The plates were washed and the spots were vi-
sualized using horseradish peroxidase–conjugated goat anti–mouse IgG1
(Southern Biotechnology Associates, Inc.), followed by 3-amino-9-ethyl- 
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carbazole substrate (AEC single step solution; Zymed Laboratories). The re-
action was terminated by washing plates with water, and the spots were
counted with the aid of a dissecting microscope.
ELISA plates coated with NP
 
17
 
-BSA or NP
 
2
 
-BSA were blocked, incu-
bated with a serial dilution of sera starting at 1:10,000, and revealed with
horseradish peroxidase–conjugated goat anti–mouse IgG followed by an in-
cubation with 3,3
 
 
 
-5,5
 
 
 
-tetramethylbenzidine substrate and an absorbance
measurement at 450 nm (1-step turbo TMB ELISA; Pierce Chemical Co.).
Titers were normalized against the value obtained for a 1:50,000 dilution of
a hyperimmunized mouse serum. This mouse had been immunized with
100 
 
 
 
g NP
 
21
 
–CGG in alum, boosted at day 30 with 50 
 
 
 
g NP
 
21
 
–CGG,
and killed at day 60 to collect serum (51).
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